Bleeding after antiplatelet therapy for the treatment of acute coronary syndromes: a review of the evidence and evolving paradigms

↓ Direkt till sidans innehåll
↓ Direkt till sidans sekundära innehåll (sidomenyn)

Search: onr:"swepub:oai:DiVA.org:uu-401385" > Bleeding after anti...

1 of 1
Previous record
Next record
To hitlist

Details
MARC

Buccheri, SergioUppsala universitet,Uppsala kliniska forskningscentrum (UCR),Kardiologi (author)

Bleeding after antiplatelet therapy for the treatment of acute coronary syndromes : a review of the evidence and evolving paradigms

Article/chapterEnglish2019

Publisher, publication year, extent ...

2019-10-25
Informa UK Limited,2019
printrdacarrier

Numbers

LIBRIS-ID:oai:DiVA.org:uu-401385
https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-401385URI
https://doi.org/10.1080/14740338.2019.1680637DOI

Supplementary language notes

Language:English
Summary in:English

Part of subdatabase

SwePubSwePub

Classification

Subject category:ref swepub-contenttype
Subject category:for swepub-publicationtype

Notes

Introduction: Potent platelet inhibition reduces the risk of thrombotic complications including myocardial infarction and death in patients with acute coronary syndrome (ACS). Targeting different pathways involved in thrombotic processes have synergistic effects and more effectively counteract thrombosis both in the acute and long-term following an ACS. Unavoidably, more potent platelet inhibition increases the risk of bleeding. In light of the adverse prognostic implications associated with bleeding, including increased mortality, safety aspects with antiplatelet therapy have gained increased importance.Areas covered: This review aims at describing the safety of different antiplatelet agents, particularly with regards to the risk of bleeding complications, used in the management of ACS patients. New bleeding reduction strategies to enhance the safety of antiplatelet therapy are also reviewed.Expert opinion: The final goal of a well-structured antiplatelet treatment strategy is that of tackling the spectrum of ischemic risk without compromising patient safety. A simple mnemonic rule for guiding therapeutic decisions in this complex clinical scenario can be summarized with the acronym ‘ABC’, meaning the sequential process of assessing, balancing and customizing treatment strategies in individual patients on the tradeoff between bleeding and ischemic risk. This approach is recommended for maximizing the ischemic benefits, while preserving safety, with the use of antiplatelet therapy.

Subject headings and genre

MEDICIN OCH HÄLSOVETENSKAP Klinisk medicin Kardiologi hsv//swe
MEDICAL AND HEALTH SCIENCES Clinical Medicine Cardiac and Cardiovascular Systems hsv//eng
Antiplatelet therapy
bleeding
risk stratification
secondary cardiovascular prevention

Added entries (persons, corporate bodies, meetings, titles ...)

Capodanno, Davide (author)
James, Stefan,1964-Uppsala universitet,Uppsala kliniska forskningscentrum (UCR),Kardiologi(Swepub:uu)stjam367 (author)
Angiolillo, Dominick J. (author)
Uppsala universitetUppsala kliniska forskningscentrum (UCR) (creator_code:org_t)

Related titles

In:Expert Opinion on Drug Safety: Informa UK Limited18:12, s. 1171-11891474-03381744-764X

Internet link

Find in a library

Expert Opinion on Drug Safety (Search for host publication in LIBRIS)

To the university's database

1 of 1
Previous record
Next record
To hitlist

Find more in SwePub

By the author/editor: Buccheri, Sergio; Capodanno, David ...; James, Stefan, 1 ...; Angiolillo, Domi ...

About the subject

MEDICAL AND HEALTH SCIENCES: MEDICAL AND HEAL ...; and Clinical Medicin ...; and Cardiac and Card ...

Articles in the publication: Expert Opinion o ...

By the university: Uppsala University

Search outside SwePub

Extend your search to:: Google; Google Book Search; Google Scholar

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

LIBRIS.kb.se